- Investing Ideas
- Swiss Biotech Stocks
Swiss Biotech Stocks
Results
15
Even though biotechnology stocks can be very risky, they can also offer some of the biggest rewards with huge profits on offer when you find the right one. The companies below all have reasonable balance sheets and value, giving the best chance of finding a gem.
15 companies
Roche Holding
Market Cap: CHF 272.7b
Engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand.
ROG
CHF 341.20
7D
-7.0%
1Y
11.1%
Novartis
Market Cap: CHF 235.2b
Researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally.
NOVN
CHF 123.26
7D
-5.5%
1Y
22.1%
Galderma Group
Market Cap: CHF 36.6b
Operates as a dermatology company worldwide.
GALD
CHF 156.00
7D
6.9%
1Y
56.9%
Sandoz Group
Market Cap: CHF 27.5b
Develops, manufactures, and markets generic and biosimilars worldwide.
SDZ
CHF 63.48
7D
-6.7%
1Y
63.5%
Bachem Holding
Market Cap: CHF 4.2b
Provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide.
BANB
CHF 55.60
7D
-6.4%
1Y
-1.0%
Siegfried Holding
Market Cap: CHF 3.5b
Engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide.
SFZN
CHF 79.10
7D
-7.7%
1Y
-14.3%
Cosmo Pharmaceuticals
Market Cap: CHF 1.7b
Focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide.
COPN
CHF 107.40
7D
-5.6%
1Y
97.8%
Tecan Group
Market Cap: CHF 1.6b
Provides laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics in Europe, North America, Asia, and internationally.
TECN
CHF 127.80
7D
-6.2%
1Y
-32.0%
Kuros Biosciences
Market Cap: CHF 1.0b
Engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally.
KURN
CHF 26.38
7D
-2.5%
1Y
33.8%
PolyPeptide Group
Market Cap: CHF 783.5m
Operates as a contract development and manufacturing company in Europe, the United States, and India.
PPGN
CHF 23.75
7D
-7.6%
1Y
21.4%
Basilea Pharmaceutica
Market Cap: CHF 639.2m
A Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections.
BSLN
CHF 52.00
7D
-5.8%
1Y
8.0%
Newron Pharmaceuticals
Market Cap: CHF 366.2m
A biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States.
NWRN
CHF 17.64
7D
-5.2%
1Y
99.3%
BioVersys
Market Cap: CHF 149.7m
A clinical stage biopharmaceutical company, focuses on identification, development, and commercialization of novel antibacterial products for serious life-threatening infections caused by multi-drug-resistant bacteria.
BIOV
CHF 25.60
7D
4.9%
1Y
-27.9%
Molecular Partners
Market Cap: CHF 145.9m
A clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland.
MOLN
CHF 3.90
7D
0.8%
1Y
-2.5%
Xlife Sciences
Market Cap: CHF 127.5m
Focuses on the development and commercialization of research projects in the life sciences sector.
XLS
CHF 22.10
7D
-1.8%
1Y
6.3%